Yükleniyor... / Loading...
This study evaluates the effectiveness of the CardioQvark single-lead ECG monitor and its software in people at risk for heart disease. It enrolled men and women aged 18 to 96 with one or more risk factors such as hypertension, diabetes, heart failure, or coronary heart disease. It was a study without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: Men and women aged 18 to 96 years who have one or more of the following risk factors: * hypertonic disease * history of ischemic stroke or transient ischemic attacks * type 1 and type 2 diabetes * 1-3 degrees obesity * heart failure or the presence of a clinic to reduce exercise tolerance associated with shortness of breath * coronary heart disease or the presence of symptoms of chest pain, in the absence of an established diagnosis of coronary heart disease * the presence of peripheral arterial atherosclerosis * the presence of a clinic of interruptions in the work of the heart (bouts of rapid, irregular heartbeats, pauses in work of heart) Non-inclusion criteria: * Acute coronary syndrome * Acute ischemic or hemorrhagic stroke * Acute psychosis * The presence of severe concomitant diseases with an expected life expectancy of less than 2 years Exclusion Criteria: Refusal of further participation in the study